Fig. 8

Patient KE-02. The model output for immunotherapeutic drug concentration under therapy for the approved 240mg q2w regimen (upper left) compared with immunotherapeutic drug concentration in a deviating regimen starting with the doubled dose (480mg) for the initial therapy cycle and subsequent 240mg q2w treatment (upper right). The doubled-dose-regimen shows better response than the standard schedule. The data points are the same as shown in Fig. 4, while the doubled-dose-regimen shows an improvement in reducing the metastatic mass by about 0.4%